Asset profile
VK2809
Small molecule
Evidence outlook · lead readout
NCT04173065 · NASH - Nonalcoholic Steatohepatitis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04173065: The study was randomized and quadruple-blinded, with placebo control and 248 participants. Its primary endpoint was the surrogate measure of relative liver-fat change on MRI-PDFF at 12 weeks, and no primary-endpoint results are posted, so the treatment comparison cannot be judged.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.